- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03988426
Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 115478
- The State Research Center, Institute of Immunology of the Federal Medical-Biological Agency
-
Moscow, Russian Federation, 117997
- Federal Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health and Social Development of the Russian Federation
-
Rostov, Russian Federation, 344022
- State Medical University
-
Saint Petersburg, Russian Federation, 197101
- Pasteur Institute
-
Yekaterinburg, Russian Federation, 620219
- Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of ≥18 years and ≤70 years.
- Confirmed diagnosis of PI requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The type of PI should be recorded.
- Patients with at least 4 infusions on regular treatment with any Intravenous Immunoglobulin (IVIG) prior to entering the study. Constant IVIG dose between 200 and 800 mg/kg body weight (the individual doses of the last 4 infusions should not vary by more than ±25% of the mean dose for the last 4 infusions).
- Availability of at least 2 IgG trough levels with an IgG level of ≥5.0 g/L from the period of the last 4 IVIG infusions.
Negative result on a pregnancy test (Human Chorionic Gonadotrophin [HCG]-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study. Women of non-childbearing potential must be post-menopausal (amenorrhoeic for at least 12 months) or surgically sterile.
Examples for medically acceptable methods of birth control for this study include:
- Oral, implantable, transdermal or injectable contraceptives
- Intrauterine device
- Condoms; diaphragm or vaginal ring with spermicidal jellies or cream
- Sexual abstinence
- Vasectomised partner
- Patient must freely give written informed consent.
- Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
Exclusion Criteria:
- Acute infection requiring intravenous (IV) antibiotic treatment within 2 weeks prior to and during the screening period.
- Known history of adverse reactions to Immunoglobulin A in other products.
- Patients with body mass index >40 kg/m2
- Exposure to blood or any blood product or plasma derivatives, other than IVIG treatment of PI, within the past 3 months prior to first infusion of octanorm.
- Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational medicinal product (IMP) (such as Polysorbate 80).
- History of malignancies of lymphoid cells and immunodeficiency with lymphoma.
- Severe liver function impairment (ALAT 3 times above upper limit of normal).
- Known protein-losing enteropathies or proteinuria.
- Presence of renal function impairment (creatinine >120 µM/L or creatinine >1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
- Treatment with enteral or parenteral steroids for ≥30 days or when given intermittently or as bolus, at daily doses ≥0.15 mg/kg. Inhaled corticosteroids are allowed.
- Patients with chronic obstructive pulmonary disease (COPD) stage Global Initiative for Chronic Obstructive Lung Disease (GOLD) III or IV.
- Treatment with immunosuppressive drugs.
- Live viral vaccination (such as measles, rubella, mumps and varicella) within the last 2 months prior to first infusion of octanorm.
- Treatment with any IMP within 3 months prior to first infusion of octanorm.
- Presence of any condition that is likely to interfere with the evaluation of study medication or satisfactory conduct of the trial.
- Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to first infusion of octanorm.
- Known or suspected human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection.
- Pregnant or nursing women; planned pregnancy during course of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Octanorm
Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver).
The initial weekly dose was determined based on subjects' previous IVIG treatment.
|
Octanorm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Serious Bacterial Infections Per Person-Year on Treatment
Time Frame: Primary Treatment Period (24 Weeks)
|
Serious Bacterial Infections defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess
|
Primary Treatment Period (24 Weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Other Infections
Time Frame: Primary Treatment Period (24 Weeks)
|
The number of patients with all infections of any kind or seriousness.
|
Primary Treatment Period (24 Weeks)
|
Number of Other Infections
Time Frame: Primary Treatment Period (24 Weeks)
|
For other infections, the Medical Dictionary for Regulatory Activities (MedDRA) preferred term was used to determine the type of infection.
They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified.
|
Primary Treatment Period (24 Weeks)
|
Time to Resolution of Infections
Time Frame: Primary Treatment Period (24 Weeks) and Whole Treatment Period (up to 36 Weeks)
|
Since infections were reported as adverse events, the time to resolution of an infection was the time from the start date of the infection adverse event to the end date of the infection adverse event.
|
Primary Treatment Period (24 Weeks) and Whole Treatment Period (up to 36 Weeks)
|
Number of Participants Using Antibiotics From 0 to > 20 Days
Time Frame: Primary Treatment Period (24 Weeks)
|
Number of patients using antibiotics during the whole treatment period (36 weeks) grouped per number of days with antibiotic usage.
|
Primary Treatment Period (24 Weeks)
|
Annual Rate of Antibiotic Use
Time Frame: Primary Treatment Period (24 Weeks)
|
The number of antibiotic treatment episodes per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment episodes / patient-years of Octanorm treatment
|
Primary Treatment Period (24 Weeks)
|
Hospitalizations Due to Infection
Time Frame: Primary Treatment Period (24 Weeks)
|
Number of days spent in hospital due to infection
|
Primary Treatment Period (24 Weeks)
|
Rate of Hospitalizations Due to Infection
Time Frame: Primary Treatment Period (24 Weeks)
|
Annual Rate of Hospitalizations due to Infection
|
Primary Treatment Period (24 Weeks)
|
Episodes of Fever
Time Frame: Primary Treatment Period (24 Weeks) and Whole Treatment Period (up to 36 Weeks)
|
Number of episodes of fever
|
Primary Treatment Period (24 Weeks) and Whole Treatment Period (up to 36 Weeks)
|
Rate of Episodes of Fever
Time Frame: Primary Treatment Period (24 Weeks)
|
The number of episodes of fever per person-year of treatment was calculated by the following formula: Total number of episodes of fever / patient-years of Octanorm treatment
|
Primary Treatment Period (24 Weeks)
|
Patients With Days Missed From Work/Study Due to Infections and Treatment
Time Frame: Primary Treatment Period (24 Weeks)
|
Total number of patients who missed days from work or study due to infections or treatment thereof.
|
Primary Treatment Period (24 Weeks)
|
Changes in the Subscales of the Form-36 Health Survey Scores From Baseline to the End of the Study
Time Frame: Baseline to the end of study (up to 36 weeks)
|
The SF-36-HS consists of 36 items organized into 8 subscales.
The 8 subscales could be combined into 2 summary scores, physical and mental.
The calculated summary scores were transformed to a range of 0-100, where a higher score indicates better health.
A positive change score indicates improvement.
|
Baseline to the end of study (up to 36 weeks)
|
Trough Levels of Serum Total IgG
Time Frame: At baseline and at last infusion (week 33)
|
Total IgG trough concentrations were measured in serum samples taken before each infusion given at the study site.
|
At baseline and at last infusion (week 33)
|
Number of Participants Experiencing Treatment-Emergent AEs
Time Frame: Up to 36 weeks
|
TEAEs were classified as temporally associated if the onset was during the infusion or within 72 hours after the end of the infusion.
|
Up to 36 weeks
|
Proportion of Infusions With at Least 1 Temporally Associated AE
Time Frame: Up to 36 weeks
|
The proportion of infusions with at least 1 temporally associated AE (TAAE) was calculated by dividing the total number of TAAE by the total number of infusions.
|
Up to 36 weeks
|
Total Number of Adverse Events Regardless of Causality
Time Frame: Up to 36 weeks
|
An AE is any untoward medical occurrence in a study patient receiving an IMP and which does not necessarily have a causal relationship with this treatment.
|
Up to 36 weeks
|
Number of Related Adverse Events
Time Frame: Up to 36 weeks
|
A related adverse event is an AE for which a causal relationship between the IMP and the AE cannot be ruled out.
|
Up to 36 weeks
|
Number of Infusions With Infusion Site Reaction
Time Frame: Up to 36 weeks
|
Total number of infusions that triggered an infusion site reaction and number of infusions that triggered mild, moderate, severe or no infusion site reactions.
|
Up to 36 weeks
|
Annual Rate of Infections
Time Frame: Up to 36 weeks
|
The annual rate of all infections of any kind of seriousness
|
Up to 36 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Wolfgang Toeglhofer, MD, Octapharma
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCGAM-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Immune Deficiency Disorder
-
ADMA Biologics, Inc.CompletedPrimary Immune Deficiency Disorders (PIDD)United States
-
University of ZurichRecruiting
-
Green Cross CorporationWithdrawnPrimary Immune Deficiency Disorder
-
Kuwait Society for Allergy and Clinical ImmunologyCompleted
-
Karolinska University HospitalCompletedPrimary Immune Deficiency DisorderSweden
-
University of ZurichRecruiting
-
OctapharmaCompletedPrimary Immune Deficiency DisorderUnited States
-
OctapharmaCompletedPrimary Immune Deficiency DisorderUnited States, Canada, Czechia, Hungary, Poland, Russian Federation, Slovakia
-
CSL BehringCompletedPrimary Immune Deficiency DisorderJapan
-
Johns Hopkins All Children's HospitalRecruitingMetabolic Disease | Primary Immune Deficiency DisordersUnited States
Clinical Trials on Octanorm
-
OctapharmaCompletedPrimary Immune Deficiency DisorderUnited States, Canada, Czechia, Hungary, Poland, Russian Federation, Slovakia
-
OctapharmaTerminatedDermatomyositisRussian Federation
-
OctapharmaCompleted